The Chronic Obstructive Pulmonary Disease (COPD) Treatment Market comprises of drugs to treat respiratory diseases characterized by long-term breathing problems and poor airflow. This includes bronchodilators, inhaled corticosteroids, combination therapies, and others that provide relief from symptoms such as breathlessness, wheezing and chronic cough. COPD has become a major cause of mortality across the world and has high prevalence among the elderly population. With increasing awareness about the availability of effective treatment options, more patients are opting for therapy.
The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 18.1 Bn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The rising smoking population worldwide is offering high growth opportunities to the COPD treatment market. According to the WHO, tobacco consumption is increasing globally with over 1.1 billion smokers. Consistent exposure to cigarette smoke is the primary risk factor for COPD development. This has led to increasing prevalence rates across countries irrespective of their economic status. Furthermore, awareness programs about the disease and available treatment options are encouraging more patients to seek therapy. Overall, the global burden of COPD cases triggered by tobacco smoking presents lucrative prospects for manufacturers in the COPD treatment market over the forecast period.
Porter's Analysis
Threat of new entrants: The COPD treatment market has moderate threat from new entrants due to high capital requirements for R&D of new drugs and devices.
Bargaining power of buyers: Individual consumers have low bargaining power, however healthcare insurers and government organizations have moderate bargaining power to negotiate prices with global players.
Bargaining power of suppliers: Suppliers of raw materials for drugs have low-moderate bargaining power due to availability of substitutes.
Threat of new substitutes: New alternative treatment methods can be a threat, however established treatment regimens have strong consumer acceptance.
Competitive rivalry: The global market is consolidated with key global players. Intense competition exists between players to develop innovative products.
SWOT Analysis
Strengths: Established brands, large R&D pipelines, global presence.
Weaknesses: High development costs, regulatory approval challenges.
Opportunities: Growth in elderly population, product innovation, emerging markets expansion.
Threats: Patent cliff of blockbuster drugs, pricing pressures, alternative treatment options.
Key Takeaways
The Global COPD Treatment Market Share is expected to witness high growth. The global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at US$ 18.1 Bn in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030.
Regional analysis related content: Asia Pacific is projected to grow at the highest CAGR during the forecast period. Growing pollution levels from vehicular emissions and industrial activities have increased COPD prevalence. China and India have a large patient pool undergoing treatment. Increasing healthcare spending by governments will drive market growth.
Key players operating in the COPD treatment market are GlaxoSmithKline, Novartis AG, Merck & Co, Abbott Laboratories, Boehringer Ingelheim, AstraZeneca, Roche Holding AG, Teva Pharmaceutical Industries, Vectura Group, Pfizer.
Get More Insights Here
The Chronic Obstructive Pulmonary Disease (COPD) was valued at US $10.78 billion in the year 2018 and is estimated to reach US $14.27 billion by 2026, at a CAGR of 3.57%.Chronic Obstructive Pulmonary Disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction and breathing difficulties.
Further, COPD symptoms include frequent coughing, increased breathlessness, wheezing and tightness in the chest.The class of drugs for the treatment of COPD includes bronchodilators, leukotriene antagonists, mast cell stabilizers and immunosuppressants.
There were around 251 million cases of COPD reported globally by WHO.
Tobacco smoking is a major risk factor for COPD and approximately 20% of smokers develop the disease and about 15–20 % of COPD cases are due to occupational exposures to pollutants at the workplace.
However, due to a surge in the industrial activities in the Asian Pacific region, especially in China, India, Vietnam, Bangladesh, etc.
Increased automotive, industrial exhaust gases are degrading air quality and have led to the increased incidence of asthma due to immense pollution, especially in the low-income population in the emerging economies.
